Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of furanone compounds in preparation of drugs for preventing or treating hyperlipidemia

A technology for hyperlipidemia and furanone, applied in the field of biomedicine, can solve the problem that furanone compounds do not show cytotoxicity and the like

Inactive Publication Date: 2019-08-23
WEIFANG MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is worth noting that within the concentration range tested, furanone compounds did not show cytotoxicity, while positive control drugs, especially LXRα agonists, showed significant cytotoxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of furanone compounds in preparation of drugs for preventing or treating hyperlipidemia
  • Application of furanone compounds in preparation of drugs for preventing or treating hyperlipidemia
  • Application of furanone compounds in preparation of drugs for preventing or treating hyperlipidemia

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0045] 1. Lipoprotein preparation

[0046] experimental method:

[0047]Lipoproteins were prepared by ultracentrifugation, the plasma density was adjusted to 1.006 g / mL, and ultracentrifuged at 400,000 × g for 24 hours at 10°C. The upper layer containing very low-density lipoprotein was removed, the density of the remaining plasma was adjusted to 1.063 g / mL, and low-density lipoprotein (LDL) was obtained by ultracentrifugation at 400,000 × g for 24 h at 10°C. Draw the upper layer containing low-density lipoprotein (LDL) and place it in the EP tube. The remaining liquid was then readjusted to a density of 1.21g / mL, and ultracentrifuged at 400,000×g for 48 h to obtain high-density lipoprotein (HDL).

[0048] HDL dialysis method: add chelated metal ions containing EDTA-2Na (0.1%, w / v) to PBS solution (pH7.2), so as to reduce oxidation during ultracentrifugation, and dialyze for 24 hours. Dialyze in EDTA-free PBS solution for 24 hours, during which the dialysate was changed 3-5...

Embodiment 1

[0050] Example 1 Cytotoxicity assay

[0051] experimental method

[0052] (1) RAW 264.7 macrophages and HepG2 cells in the logarithmic growth phase were first mixed with 1×10 3 cells / mL were inoculated in 96-well plates, and 0.2 mL of 10% DMEM medium was added to each well, and cultured for 12 hours.

[0053] (2) RAW 264.7 macrophages and HepG2 cells were treated with furanone compounds, fenofibrate and LXR activator (T0901317), respectively, and the final concentrations of the drugs were set to 0 μM, 2.5 μM, 5 μM, 8 μM and 10 μM. μM. The medium is DMEM (10% fetal bovine serum) medium. Set more than 3 parallel wells in each group, set at 37°C, 5% CO 2 Continue culturing for 24 h in the incubator.

[0054] (3) After the culture, the supernatant was discarded, and 20 μL of 5.0 mg / mL MTT was added to each well. The cells were incubated for an additional 4 hours to form formazan crystals.

[0055] (4) Carefully discard the supernatant, add 150 μl of DMSO to each well to dis...

Embodiment 2

[0058] Example 2 Oil Red O staining

[0059] experimental method

[0060] (1) RAW 264.7 macrophages or HepG2 cells were mixed with 2×10 cells per well 4 The final density of cells was seeded into 6-well plates. After 12 hours, the medium was aspirated off and the cells were washed 3 times with PBS.

[0061] (2) Then, add 1.5 mL of ox-LDL containing 1% FBS and a final concentration of 50 mg / mL to each well of RAW 264.7 macrophages, and continue to incubate for 24 hours; add 1.5 mL of 1% FBS to each well of HepG2 cells and oleic acid (0.5mM) medium, and continue to incubate for 24 hours.

[0062] (3) After the incubation, gently wash the cells 3 times with PBS. Set blank group (DMEM medium), control group T0901317 (5 μM), and experimental group furanone compounds (5 μM) to treat RAW 264.7 macrophages. Add 500 μl of DMEM medium (containing 1% FBS) containing the above drugs to each well to treat the cells for 4 hours. Groups were set up according to the same experimental me...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of furanone compounds in preparation of drugs for preventing or treating hyperlipidemia, belongs to the field of biomedicine, and relates to medical application offuranones, the detection of the lipid-lowering activity of furanone compounds and the study of acting mechanisms. Through related experiments, it is proved that the furanone compounds can promote cholesterol efflux and affect the expression of key genes and protein in a reverse transport process of cholesterol, so that good lipid-lowering activity is obtained, and at the same time, a potential lipid-lowering mechanism of the furanone compounds is revealed.

Description

technical field [0001] The invention relates to the medical use of furanone compounds, in particular to the application of furanone compounds in the preparation of drugs for preventing or treating hyperlipidemia, and belongs to the field of biomedicine. Background technique [0002] Hyperlipidemia is a major inducer of atherosclerosis, primarily by promoting the formation and accumulation of lipid plaques in arteries. Reverse cholesterol transport (RCT) refers to the process of transporting cholesterol in extrahepatic tissue cells to the liver through blood circulation, and undergoes metabolic transformation in liver cells. This pathway is of great significance for reducing the accumulation of cholesterol in blood vessel walls. [0003] The vast ocean accounts for 71% of the earth's surface. Because of the uniqueness of high salinity, high pressure, low temperature and special light, the marine environment determines that marine life is different from terrestrial life. Over...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/365A61P3/06
CPCA61K31/365A61P3/06
Inventor 郭守东宋伟国李婷王进杨晓倩夏彬
Owner WEIFANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com